Skip to main content

Table 2 Association between SAF and the history of myocardial infarction

From: Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study

 

n/N

OR for prevalent myocardial infarction (95% CI)

Crude model

Model 1

Model 2

Model 3

SAF tertilesa

 Low SAF

52/999

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 Medium SAF

79/998

1.57 (1.09, 2.25)

1.72 (1.19, 2.50)

1.76 (1.20, 2.59)

1.72 (1.17, 2.54)

 High SAF

98/999

1.98 (1.40, 2.81)

1.98 (1.39, 2.84)

1.93 (1.33, 2.8)

1.87 (1.28, 2.73)

One-unit increase

229/2996

2.61 (2.03, 3.35)

1.71 (1.29, 2.26)

1.63 (1.22, 2.18)

1.57 (1.16, 2.12)

  1. n/N: number of individuals who had myocardial infarction/sample size of the group
  2. ORs and 95% CIs are adjusted odds ratios and the respective 95% confidence intervals of myocardial infarction in association with one unit higher SAF or of the medium and high SAF groups when compared to the low SAF group
  3. The crude model: was not adjusted for covariates
  4. Model 1 adjusted for age, sex, and RS subcohorts
  5. Model 2 adjusted for age, sex, RS subcohorts, body mass index, dyslipidemia, and hypertension
  6. Model 3 adjusted for age, sex, RS subcohorts, body mass index, dyslipidemia, hypertension, smoking status, diabetes, and eGFR
  7. aSex-specific, age-adjusted SAF tertiles were calculated among n = 3001 participants
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840